Effect of CCR2-V64I on the Susceptibility of Patients to Cancer

Background. Results from the studies investigating the impact of CC chemokine receptor 2 (CCR2) polymorphism on the risk of cancers are diverse. An updated meta-analysis was conducted to access the relationship between cancer risk and CCR2-V64I polymorphism. Methods. We performed a meta-analysis using STATA 11.0 based on a comprehensive retrieval in WanFang Data, PubMed, China National Knowledge Infrastructure, EMBASE, and Web of Science databases up to January 20, 2023. Results. We included 23 studies in our analysis. Overall, we found CCR2-V64I polymorphism was remarkably related to cancer risk (OR = 1.39, 95% CI = 1.14-1.70, and P=0.001 for A vs G; OR = 1.87, 95% CI = 1.30-2.70, and P=0.001 for AA vs GG; OR = 1.35, 95% CI = 1.03-1.78, and P=0.032 for GA vs GG; OR = 1.45, 95% CI = 1.11-1.90, and P=0.006 for AA + GA vs GG; OR = 1.69, 95% CI = 1.20-2.37, and P=0.003 for AA vs GA + GG). In the ethnicity subgroup analysis, the relevancy between CCR2-V64I polymorphism and an increased cancer risk was discovered among Asians (OR = 1.57, 95% CI = 1.30-1.91, and P<0.001 for A vs G; OR = 2.30, 95% CI = 1.64-3.24, and P<0.001 for AA vs GG; OR = 1.35, 95% CI = 1.10-1.67, and P=0.005 for GA vs GG; OR = 1.52, 95% CI = 1.25-1.87, and P<0.001 for AA + GA vs GG; OR = 2.21, 95% CI = 1.58-3.08, and P<0.001 for AA vs GA + GG). In addition, the subgroup analysis in the light of cancer types demonstrated that CCR2-V64I polymorphism was strongly correlated with bladder cancer (OR = 3.04, 95% CI = 1.09-8.45, and P=0.033 for AA vs GG; OR = 2.84, 95% CI = 1.07-7.09, and P=0.035 for AA vs GA + GG) and oral cancer (OR = 1.83, 95% CI = 1.39-2.42, and P<0.001 for A vs G; OR = 2.04, 95% CI = 1.47-2.85, and P<0.001 for GA vs GG; OR = 2.03, 95% CI = 1.48-2.79, and P<0.001 for AA + GA vs GG). Conclusion. The meta-analysis suggested that CCR2-V64I polymorphism might be a high-risk factor for cancers among Asians, especially for bladder and oral cancers.

Automated summary

This meta-analysis found a significant association between CCR2-V64I polymorphism and cancer risk, particularly among Asians, with a higher risk observed for bladder and oral cancers.